When should iron chelation therapy be considered in patients with myelodysplasia and other bone marrow failure syndromes with iron overload?

dc.contributor.authorBird, R.
dc.contributor.authorKenealy, M.
dc.contributor.authorForsyth, C.
dc.contributor.authorWellwood, J.
dc.contributor.authorLeahy, M.
dc.contributor.authorSeymour, J.
dc.contributor.authorTo, L.
dc.date.issued2012
dc.description.abstractDespite the absence of a robust evidence base, there is growing consensus that effective treatment of iron overload leads to decreased morbidity and premature mortality in patients with good prognosis myelodysplastic syndromes (MDSs). Furthermore, new treatment modalities, including disease-modifying therapies (lenalidamide and azacytidine) and reduced intensity conditioning therapies for allogeneic blood stem cell transplants, are offering the prospect of longer survival for patients with traditionally less favourable prognosis MDS, who might also benefit from iron chelation. This article proposes assessment of patients with MDS and related bone marrow failure syndromes to determine suitability for iron chelation. Iron chelation therapy options and monitoring are discussed.
dc.description.statementofresponsibilityR.J. Bird, M. Kenealy, C. Forsyth, J. Wellwood, M.F. Leahy, J.F. Seymour and L.B. To
dc.identifier.citationInternal Medicine Journal, 2012; 42(4):450-455
dc.identifier.doi10.1111/j.1445-5994.2012.02734.x
dc.identifier.issn1444-0903
dc.identifier.issn1445-5994
dc.identifier.urihttp://hdl.handle.net/2440/72892
dc.language.isoen
dc.publisherBlackwell Publishing Asia
dc.rights© 2012 The Authors. Internal Medicine Journal © 2012 Royal Australasian College of Physicians
dc.source.urihttps://doi.org/10.1111/j.1445-5994.2012.02734.x
dc.subjectMyeodysplasia
dc.subjectiron
dc.subjectchelation
dc.titleWhen should iron chelation therapy be considered in patients with myelodysplasia and other bone marrow failure syndromes with iron overload?
dc.typeJournal article
pubs.publication-statusPublished

Files